Q-omics provides the consensus-scored PRICKLE3 profile across patient tissues and cancer cell-line models. PRICKLE3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PRICKLE3 is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, PRICKLE3 RNA expression shows 19,272 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KICH, COAD, and KIRP as cancer lineages where PRICKLE3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRICKLE3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRICKLE3 survival associations across molecular data types. PRICKLE3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRICKLE3 RNA expression–survival associations across cancer types. High PRICKLE3 expression shows unfavorable associations in KICH, KIRP, LGG and LIHC, but favorable associations in BLCA and SCLC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for PRICKLE3 RNA expression.
This table summarizes PRICKLE3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PRICKLE3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRICKLE3 shows higher tumor expression in COAD, HNSC, KIRC, LIHC, LUAD and LUSC. The COAD box plot shows higher PRICKLE3 RNA expression in tumor versus normal tissue (log2 FC = +1.198, t-test p < 0.001).
This table shows molecular features associated with PRICKLE3 in patient tissues and cancer cell lines. In patient samples, PRICKLE3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, PRICKLE3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
